LUPIN LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,588 INR | +0.65% |
|
-1.60% | +20.02% |
| May. 30 | India's pharma export sales to grow faster this year, trade body says | RE |
| May. 27 | Indian drugmakers to see FY25 revenue boost in key US market, says India Ratings and Research | RE |
| Sales 2024 | 200B 2.4B | Sales 2025 * | 217B 2.6B | Capitalization | 724B 8.68B |
|---|---|---|---|---|---|
| Net income 2024 | 19.14B 230M | Net income 2025 * | 24.09B 289M | EV / Sales 2024 | 3.68 x |
| Net Debt 2024 * | 24.9B 299M | Net cash position 2025 * | 356M 4.26M | EV / Sales 2025 * | 3.34 x |
| P/E ratio 2024 |
38.6
x | P/E ratio 2025 * |
30.1
x | Employees | 20,933 |
| Yield 2024 * |
0.45% | Yield 2025 * |
0.54% | Free-Float | 52.85% |
More Fundamentals
* Assessed data
More news
Latest transcript on Lupin Limited
More recommendations
More press releases
More news
| 1 day | +0.65% | ||
| 1 week | -1.60% | ||
| 1 month | -3.50% | ||
| 3 months | -1.91% | ||
| 6 months | +23.97% | ||
| Current year | +20.02% |
1 week
1 572.55
1 648.00
1 month
1 561.001 727.90
Current year
1 332.101 727.90
1 year
805.401 727.90
3 years
583.051 727.90
5 years
505.001 727.90
10 years
505.002 127.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 96-12-31 | |
Johnny Mikell
PSD | President | - | - |
| Director of Finance/CFO | 59 | 07-08-12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 74 | 15-10-26 | |
Mark McDade
BRD | Director/Board Member | 69 | 21-01-27 |
| Director/Board Member | 50 | 95-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.38% | 6 M€ | +6.07% | - | |
| 0.12% | 11 M€ | +2.67% | ||
| 0.04% | 454 M€ | +4.02% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 1,588 | +0.65% | 7,767 |
| 24-05-30 | 1,578 | -1.48% | 7,450 |
| 24-05-29 | 1,601 | -0.14% | 30,251 |
| 24-05-28 | 1,604 | -0.75% | 8,628 |
| 24-05-27 | 1,616 | +0.12% | 14,935 |
Delayed Quote Bombay S.E., May 31, 2024 at 06:15 am EDT
More quotes
Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas:
- design and production of generic and brand-name formulations;
- production of active pharmaceutical ingredients.
At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil.
Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).
Sector
Pharmaceuticals
Calendar
2024-08-06
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
HOLD
Number of Analysts
35
Last Close Price
1,588
INR
Average target price
1,581
INR
Spread / Average Target
-0.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +20.02% | 8.67B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- LUPIN Stock
